OncoSec Medical Inc (ONCSQ)

[hschlauch]

Adam missed the biggest distinction of them all...

The Epacadostat plus pembro combination ECHO 202 trial had enrolled (almost entirely) treatment naive patients, i.e. no prior therapies, whereas the Immunopulse IL-12 combo trial had enrolled patients who had failed prior therapies AND had very low percentages of the partially exhausted T cell phenotype. Some even had no detectable partially exhausted cells at all at baseline.

Moreover, the complete response numbers from the Immunopulse IL-12 and pembro combo is over 40%, and the Epac combo was around 14%. Nearly every single responder in the Immunopulse IL-12 and pembro trial is seeing a complete response.

Also, duration of response and the safety profile are shaping up to be better than Epac plus pembro.